In the last few years, there have been increasing reports from medical professionals of patients that have undergone the use of osimertinib for the treatment of hair loss. There have also been reports of significant improvements in the quality of the skin of these patients. Some people have even reported that they are seeing results from their treatment that are greater than what they would have expected to see. The question then becomes, does this treatment work?
To answer this question, it is important to understand what is meant by the statistical significance of an intervention and whether or not it is feasible to compare AZD-9291 with other treatments on a similar scale such as minoxidil.
One way to compare the effects of this medication is to look at what effect it has on hair follicular function. This is measured by the percent of total hair that grows per month in comparison to the total hair that was shed during the 6 month period. This is called the median duration of hair growth. If the patient’s hair grows in a statistically significant amount during the 6 months of the study, then this is a good indication that the medication is working.
At the same time, if the percent of hair loss is greater than the median duration, then this may suggest that the hair follicles are not responding to the drug’s stimulation in the way that they should be.
Using data such as these to make an informed decision about the efficacy of osimertinib for patients will require the use of a placebo control trial. In a placebo-control trial, half of the patients taking the medication undergo a double blind procedure where they are told that they are actually getting the placebo while the rest of the patients are placed in a similar group that has no such information available.
It is expected that the patients who undergo a placebo control trial will not report any differences in the percent of hair that grows per month between these groups, but it is also possible that there will be some improvements noted among these placebo participants.
However, the use of placebo in clinical trials is not without controversy. Proponents of osimertinib believe that it is better to allow patients to report their own results rather than waiting for trial results to be validated by other experts.
However, some experts argue that while the use of placebo in these trials can reduce the potential for patients to experience unpleasant side effects, there is no method to control for possible disease recurrence. There is always the possibility that a patient will develop a disease back after starting on an anti-hair-loss regimen.
There are other factors that need to be considered when evaluating whether osimertinib will have a positive effect on patients with alopecia areata. If the treatment does not seem to work after four to six months of therapy, it is generally recommended that patients discontinue the medication.
Some of the medications used in the trials showed significant improvements in patients who were given the placebo, but these improvements were not significant when comparing those who took the higher doses of osimertinib with those who received the lower doses. If you want know more, you can visit https://www.aasraw.com/products/lenvatinib/.